Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

In a westward expansion, FreezPak Logistics is taking up residence in its first West Coast facility: a new cold storage ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

Blockbuster weight loss drug Ozempic could get cheaper by 2027, as it's on the list of medications the government is ...

GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

GLP-1 drug users initially spend less on groceries, but that levels out over the next year, shows Circana's analysis of food ...

Unless you have no TV or Internet, you’ve likely heard of the GLP-1 craze – glossy commercials and ads featuring people ...

New data suggest Restylane Lyft or Contour in combination with Sculptra corrects contour deficiencies in patients ...